Clinical trials: High Risk Medications
High Grade Osteosarcoma, Localized Osteosarcoma
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating…
- Conditions
- High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
- Trial name
- NCT05691478
- Testing
- Bone Scan, Cabozantinib S-malate, Cisplatin
- Where
- 202 sites in United States, Australia and 2 more
- Volunteers
- 1,122 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet…
- Trial name
- HEIGHTEN (NCT01869309)
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- LifeBridge Health
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in…
- Conditions
- Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Adverse Reaction to Drug, Vascular Endothelial Growth Factor Overexpression
- Trial name
- NCT02447679
- Testing
- thalidomine, tegafur-uracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Stroke, Transient Ischemic Attack (TIA)
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic…
- Trial name
- CYP-FAST (NCT06943586)
- Testing
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Chronic Kidney Disease, Pneumonia
Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients
Chronic kidney disease is a severe medical problem in Taiwan public health issue, which the highest incidence and prevalence rate in the world.Proton pump inhibitors may increase the risk of pneumonia appearance, which were…
- Trial name
- NCT01588886
- Volunteers
- 9,000 people
- Sponsor
- Far Eastern Memorial Hospital
Antimicrobial Drug Resistance, High-Throughput Nucleotide Sequencing
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
This observational study is to learn about the predictive value of targeted next-generation sequencing(tNGS) in pathogen resistance phenotype of patients with lower respiratory tract infection ,by detecting…
- Trial name
- NCT07035535
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pain, Quality of Life
FLUAD® vs. Fluzone® High-Dose Study
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug
- Trial name
- NCT03183908
- Testing
- FLUAD®, Fluzone® High-Dose
- Where
- 4 sites in United States
- Volunteers
- 757 people, healthy volunteers welcome
- Sponsor
- Duke University
Acute Disease
High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department
This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or…
- Trial name
- NCT07278648
- Testing
- Antithrombotic therapy
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Acute Kidney Injury
AKI in Thoracic and Abdominal Surgery
The study will investigate the role of NSAIDs in the development of AKI in patients undergoing high-risk abdominal or thoracic surgery.
- Trial name
- NCT02553174
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Milton S. Hershey Medical Center
Glioma, Astrocytic
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
This is an interventional, non-randomized, single site study. Brain tumor samples will be collected from patients for organoids generation and subject to panel drugs screening and QPOP analysis to derive the optimal drug…
- Trial name
- NCT05532397
- Testing
- QPOP category 1, QPOP category 2
- Where
- 2 sites in Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
The purpose of this study is to evaluate whether adding olanzapine 5mg to standard antiemetic medication can significantly reduce chemotherapy-induced nausea and vomiting in breast cancer patients receiving emetogenic…
- Trial name
- NCT02861859
- Testing
- Olanzapine
- Where
- Canada
- Volunteers
- 221 people
- Sponsor
- Ottawa Hospital Research Institute
Healthy Volunteers
A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
The purpose of this study is to assess the bioavailability of two different doses of venetoclax new high drug load formulation tablets relative to two tablets of the currently marketed venetoclax tablets under fed conditions.
- Trial name
- NCT06070948
- Testing
- Venetoclax
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AbbVie
Soft Tissue Sarcoma, Child
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and…
- Trial name
- NCT07528079
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Intractable Epilepsy, Malignant Glioma
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures.
- Conditions
- Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma
- Trial name
- NCT04650204
- Testing
- Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Coronary Heart Disease (CHD)
Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease
The goal of this exploratory clinical trial is to investigate the proteomic changes induced by low-dose colchicine anti-inflammatory therapy in coronary heart disease (CHD) patients, with the aim of identifying novel biomarkers…
- Trial name
- PIC-CHD (NCT07462325)
- Testing
- colchicine
- Volunteers
- 176 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Breast Cancer
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual…
- Trial name
- NCT05677308
- Where
- 38 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Multiple Sclerosis, Long COVID
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making…
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese
- Trial name
- NCT06171152
- Testing
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Acute Otitis Media
Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence
The purpose of this study is to study whether a herbal-based medication is superior to placebo for prevention of acute otitis media in pre-school children with upper respiratory tract infection.
- Trial name
- OTV_PRE_01 (NCT02345447)
- Testing
- Herbal-based medication
- Where
- Germany
- Volunteers
- 296 people
- Sponsor
- University Hospital Tuebingen
High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG)
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
- Conditions
- High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
- Trial name
- NCT07455045
- Testing
- FZ-AD005
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.